Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells

Journal of NeuroVirology

Volumn 14, Issue 5, 2008, Pages 448-454

  Chapagain, Moti L ^a   Sumibcay, Laarni ^a   Gurjav, Ulziijargal ^a,b   Kaufusi, Pakieli ^a   Kast, Richard E ^c   Nerurkar, Vivek R ^a,b  

^a Asia Pacific Institute of Tropical Medicine and Infectious Diseases   (United States)

^b UNIVERSITY OF HAWAII AT MANOA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Human polyomavirus; JCV; Mirtazapine; PML; Risperidone; Serotonin receptor

Indexed keywords

MESSENGER RNA; RISPERIDONE; SEROTONIN 2A ANTAGONIST;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; FETUS; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; JC VIRUS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

CELL LINE; FETUS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; JC VIRUS; NEUROGLIA; POLYOMAVIRUS INFECTIONS; RECEPTOR, SEROTONIN, 5-HT2A; RISPERIDONE; VIRUS REPLICATION;

JC POLYOMAVIRUS; POLYOMAVIRUS;

EID: 57049189593     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280802235916     Document Type: Article

References (35)

1. Agostini, HT, Deckhut, A., Jobes, DV, Girones, R., Schlunck, G., Prost, MG, Frias, C., Perez-Trallero, E., Ryschkewitsch, CF and Stoner, GL (2001) Genotypes of JC virus in East, Central and Southwest Europe. J Gen Virol, 82, pp. 1221-1331.
2. Agostini, HT, Ryschkewitsch, CF, Singer, EJ and Stoner, GL (1997) JC virus regulatory region rearrangements and genotypes in progressive multifocal leukoencephalopathy: Two independent aspects of virus variation. J Gen Virol, 78, pp. 659-664.
3. Agostini, HT, Ryschkewitsch, CF and Stoner, GL (1996) Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol, 34, pp. 159-164.
4. Aksamit, AJ (2001) Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J NeuroVirol, 7, pp. 386-390.
5. Altschuler, EL and Kast, RE (2005) The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses, 65, pp. 585-586.
6. Antinori, A., Ammassari, A., Giancola, ML, Cingolani, A., Grisetti, S., Murri, R., Alba, L., Ciancio, B., Soldani, F., Larussa, D., Ippolito, G. and De Luca, A. (2001) Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J NeuroVirol, 7, pp. 323-328.
7. Antinori, A., Cingolani, A., Lorenzini, P., Giancola, ML, Uccella, I., Bossolasco, S., Grisetti, S., Moretti, F., Vigo, B., Bongiovanni, M., Del Grosso, B, Arcidiacono, MI, Fibbia, GC, Mena, M., Finazzi, MG, Guaraldi, G., Ammassari, A., d'Arminio Monforte, A, Cinque, P. and De Luca, A. (2003) Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). J NeuroVirol, 9, pp. 47-53.
8. Chapagain, ML, Nguyen, T., Bui, T., Verma, S. and Nerurkar, VR (2006) Comparison of real-time PCR and hemagglutination assay for quantitation of human polyomavirus JC. Virol J, 3, p. 3.
9. Chapagain, ML, Verma, S., Mercier, F., Yanagihara, R. and Nerurkar, VR (2007) Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology, 364, pp. 55-63.
10. Co, JK, Verma, S., Gurjav, U., Sumibcay, L. and Nerurkar, VR (2007) Interferon- alpha and-beta restrict polyomavirus JC replication in primary human fetal glial cells: Implications for progressive multifocal leukoencephalopathy therapy. J Infect Dis, 196, pp. 712-718.
11. Colosimo, C., Lebon, P., Martelli, M., Tumminelli, F. and Mandelli, F. (1992) Alpha-interferon therapy in a case of probable progressive multifocal leukoencephalopathy. Acta Neurol Belg, 92, pp. 24-29.
12. De Luca, A., Giancola, ML, Ammassari, A., Grisetti, S., Cingolani, A., Larussa, D., Alba, L., Murri, R., Ippolito, G., Cauda, R., Monforte, A. and Antinori, A. (2001) Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. J NeuroVirol, 7, pp. 364-368.
13. De Luca, A., Giancola, ML, Cingolani, A., Ammassari, A., Gillini, L., Murri, R. and Antinori, A. (1999) Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin Infect Dis, 28, pp. 624-628.
14. Decker, M., Schleifer, KJ, Nieger, M. and Lehmann, J. (2004) Dopamine/ serotonin receptor ligands. Part VIII: The dopamine receptor antagonist LE300-modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testings. Eur J Med Chem, 39, pp. 481-489.
15. Dubois, V., Moret, H., Lafon, ME, Brodard, V., Icart, J., Ruffault, A., Guist'hau, O., Buffet-Janvresse, C., Abbed, K., Dussaix, E. and Ingrand, D. (2001) JC virus genotypes in France: Molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis, 183, pp. 213-217.
16. Elphick, GF, Querbes, W., Jordan, JA, Gee, GV, Eash, S., Manley, K., Dugan, A., Stanifer, M., Bhatnagar, A., Kroeze, WK, Roth, BL and Atwood, WJ (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science, 306, pp. 1380-1383.
17. Enting, RH and Portegies, P. (2000) Cytarabine and highly active antiretroviral therapy in HIV-related progressive multifocal leukoencephalopathy. J Neurol, 247, pp. 134-138.
18. Focosi, D., Fazzi, R., Montanaro, D., Emdin, M. and Petrini, M. (2007) Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: A clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res, 74, pp. 156-158.
19. Focosi, D., Kast, RE, Maggi, F., Ceccherini-Nelli, L. and Petrini, M. (2007) Risperidone-induced reduction in JC viruria as a surrogate marker for efficacy against progressive multifocal leukoencephalopathy and hemorrhagic cystitis. J Clin Virol, 39, pp. 63-64.
20. Geschwind, MD, Skolasky, RI, Royal, WS and McArthur, JC (2001) The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J NeuroVirol, 7, pp. 353-357.
21. Huang, SS, Skolasky, RL, Dal Pan, GJ, Royal 3rd, W. and McArthur, JC (1998) Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: An observational study. J NeuroVirol, 4, pp. 324-332.
22. Lima, MA, Katz-Brull, R., Lenkinski, RE, Nunez, R., Feinrider, D. and Koralnik, IJ (2007) Remission of progressive multifocal leukoencephalopathy and primary central nervous system lymphoma in an HIV-infected patient. Eur J Neurol, 14, pp. 598-602.
23. Marra, CM, Rajicic, N., Barker, DE, Cohen, BA, Clifford, D., Donovan Post, MJ, Ruiz, A., Bowen, BC, Huang, ML, Queen-Baker, J., Andersen, J., Kelly, S. and Shriver, S. (2002) A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS, 16, pp. 1791-1797.
24. Maxishima, M., Shiga, T., Shutoh, F., Hamada, S., Maeshima, T. and Okado, N. (2001) Serotonin 2A receptor-like immunoreactivity is detected in astrocytes but not in oligodendrocytes of rat spinal cord. Brain Res, 889, pp. 270-273.
25. Morisset, S., Sahm, UG, Traiffort, E., Tardivel-Lacombe, J., Arrang, JM and Schwartz, JC (1999) Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther, 288, pp. 590-596.
26. Nath, A., Venkataramana, A., Reich, DS, Cortese, I. and Major, EO (2006) Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology, 66, pp. 149-150.
27. O'Hara, BA and Atwood, WJ (2008) Interferon beta1-a and selective anti-5HT(2a) receptor antagonists inhibit infection of human glial cells by JC virus. Virus Res, 132, pp. 97-103.
28. Owczarczyk, K., Hilker, R., Brunn, A., Hallek, M. and Rubbert, A. (2007) Progressive multifocal leucoencephalopathy in a patient with sarcoidosis-successful treatment with cidofovir and mirtazapine. Rheumatology (Oxford), 46, pp. 888-890.
29. Padgett, BL, Rogers, CM and Walker, DL (1977) JC virus, a human polyomavirus associated with progressive multifocal leukoencephalopathy: additional biological characteristics and antigenic relationships. Infect Immun, 15, pp. 656-662.
30. Padgett, BL, Walker, DL, ZuRhein, GM, Eckroade, RJ and Dessel, BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet, 1, pp. 1257-1260.
31. Santagata, S. and Kinney, HC (2005) Mechanism of JCV entry into oligodendrocytes. Science, 309, pp. 381-382.
32. Shah, KV, Daniel, RW, Strickler, HD and Goedert, JJ (1997) Investigation of human urine for genomic sequences of the primate polyomaviruses simian virus 40, BK virus, and JC virus. J Infect Dis, 176, pp. 1618-1621.
33. Verma, S., Cikurel, K., Koralnik, IJ, Morgello, S., Cunningham-Rundles, C., Weinstein, ZR, Bergmann, C. and Simpson, DM (2007) Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis, 196, pp. 709-711.
34. Vulliemoz, S., Lurati-Ruiz, F., Borruat, FX, Delavelle, J., Koralnik, IJ, Kuntzer, T., Bogousslavsky, J., Picard, F., Landis, T. and Du Pasquier, RA (2006) Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry, 77, pp. 1079-1082.
35. Wyen, C., Hoffmann, C., Schmeisser, N., Wohrmann, A., Qurishi, N., Rockstroh, J., Esser, S., Rieke, A., Ross, B., Lorenzen, T., Schmitz, K., Stenzel, W., Salzberger, B. and Fatkenheuer, G. (2004) Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: Survival and risk factors of death. J Acquir Immune Defic Syndr, 37, pp. 1263-1268.